Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Feb 20, 2025
Emerging Company Profile
Switch: Precision siRNA knockdown
San Francisco-based biotech is pursuing CNS diseases with three-stranded siRNAs that can target specific cell types within a tissue
BioCentury | Nov 27, 2024
Product Development
Biohaven’s Phase III SMA miss: was it the target or the trial design?
BioCentury’s latest Clinical Report also analyzes results from Alector, NewAmsterdam and Pyxis that led shares to slip, and more
BioCentury | Nov 11, 2024
Product Development
AbbVie’s schizophrenia miss: implications for itself, BMS and M4 pipeline
Price tag of AbbVie’s Cerevel deal now harder to justify, as BMS’s first-mover advantage extends and M4 PAMs come into question
BioCentury | Oct 9, 2024
Product Development
How to establish causality via patient observation
Strategies to find targets in patient data are largely grounded in genetics, but the toolbox is diversifying, and increasingly longitudinal
BioCentury | Sep 25, 2024
Discovery & Translation
Mapping genetics to the medical phenome: Case studies from Vanderbilt
Quantitative human geneticist Nancy Cox on insights from longitudinal EHRs, biobank data, and value to drug developers
BioCentury | Sep 24, 2024
Deals
Ventyx deal a sign of Sanofi’s growing interest neuro-immunology?
Deals Report: Novo Nordisk tapping NanoVation delivery tech, Organon acquires Dermavant, Telix expands U.S. radiopharma footprint, and more
BioCentury | Jun 29, 2024
Discovery & Translation
Science Spotlight: Microglial transplantation for ALSP, AlaMab’s osteosarcoma mAb and more
BioCentury’s roundup of translational innovations
BioCentury | Apr 2, 2024
Product Development
Neurology’s false choice: symptomatic vs. disease-modifying
A new theme in Alzheimer’s is aiming for early symptom relief PLUS long-term disease modification
BioCentury | Jan 18, 2024
Discovery & Translation
Proteomics study identifies five subtypes of Alzheimer’s
Each one may require different treatments and have different safety considerations
Items per page:
1 - 10 of 53